Researchers from Baylor College of Medicine and Texas Children's Hospital detailed the discovery of CPK-03-37, a novel fluorescent organic molecule for tumor imaging.

3B Pharmaceuticals has divulged conjugates comprising fibroblast activation protein alpha (FAPalpha) inhibitors covalently linked to radiolabeled chelating agents through a linker acting as single-photon emission computed tomography (SPECT)/CT imaging agents reported to be useful for the diagnosis and treatment of cancer.